ACR2022 - Day 4.1

Get the Skinny on Bimekizumab in PsADr. Janet Pope discusses abstract presented at ACR22 Convergence in Philadelphia, PA.L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study Low dose steroids can negatively impact bone healthDr. Janet Pope discusses abstract L01 presented at ACR22 Convergence in Philadelphia, PA. L01: Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study The First Head to Head trial in Axial SpondyloarthritisDr. Lianne Gensler discusses abstract L15 presented at ACR22 Convergence in Philadelphia, PA.L15: Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: A Randomized Phase IIIb Study Why Clinical Trials?Dr. Guillermo Valenzuela talks about the importance of clinical trials from ACR22 Convergence in Philadelphia, PA.